OBJECTIVE: To conduct a cost-benefit analysis of Early Start, an integrated prenatal intervention program for stopping substance use in pregnancy. METHODS: A retrospective cohort study was conducted of 49,261 women who had completed prenatal substance abuse screening questionnaires at obstetric clinics and who had undergone urine toxicology screening tests. Four study groups were compared: women screened and assessed positive and followed by Early Start (screened-assessed-followed, n=2,032), women screened and assessed positive without follow-up (screened-assessed, n=1,181), women screened positive only (screened-positive-only, n=149), women in the control group who screened negative (control, n=45,899). Costs associated with maternal health care (prenatal through 1 year postpartum), neonatal birth hospitalization care, and pediatric health care (through 1 year) were adjusted to 2009 dollars. Mean costs were calculated and adjusted for age, race, education, income, marital status, and amount of prenatal care. RESULTS: Screened-positive-only group adjusted mean maternal total costs ($10,869) were significantly higher than screened-assessed-followed, screened-assessed, and control groups ($9,430; $9,230; $8,282; all P<.001). Screened-positive-only group adjusted mean infant total costs ($16,943) were significantly higher than screened-assessed-followed, screened-assessed, and control groups ($11,214; $11,304; $10,416; all P<.001). Screened-positive-only group adjusted mean overall total costs ($27,812) were significantly higher than screened-assessed-followed, screened-assessed, and control groups ($20,644; $20,534; $18,698; all P<.001). Early Start implementation costs were $670,600 annually. Cost-benefit analysis showed that the net cost benefit averaged $5,946,741 per year. CONCLUSION: Early Start is a cost-beneficial intervention for substance use in pregnancy that improves maternal-infant outcomes and leads to lower overall costs by an amount significantly greater than the costs of the program.
OBJECTIVE: To conduct a cost-benefit analysis of Early Start, an integrated prenatal intervention program for stopping substance use in pregnancy. METHODS: A retrospective cohort study was conducted of 49,261 women who had completed prenatal substance abuse screening questionnaires at obstetric clinics and who had undergone urine toxicology screening tests. Four study groups were compared: women screened and assessed positive and followed by Early Start (screened-assessed-followed, n=2,032), women screened and assessed positive without follow-up (screened-assessed, n=1,181), women screened positive only (screened-positive-only, n=149), women in the control group who screened negative (control, n=45,899). Costs associated with maternal health care (prenatal through 1 year postpartum), neonatal birth hospitalization care, and pediatric health care (through 1 year) were adjusted to 2009 dollars. Mean costs were calculated and adjusted for age, race, education, income, marital status, and amount of prenatal care. RESULTS: Screened-positive-only group adjusted mean maternal total costs ($10,869) were significantly higher than screened-assessed-followed, screened-assessed, and control groups ($9,430; $9,230; $8,282; all P<.001). Screened-positive-only group adjusted mean infant total costs ($16,943) were significantly higher than screened-assessed-followed, screened-assessed, and control groups ($11,214; $11,304; $10,416; all P<.001). Screened-positive-only group adjusted mean overall total costs ($27,812) were significantly higher than screened-assessed-followed, screened-assessed, and control groups ($20,644; $20,534; $18,698; all P<.001). Early Start implementation costs were $670,600 annually. Cost-benefit analysis showed that the net cost benefit averaged $5,946,741 per year. CONCLUSION: Early Start is a cost-beneficial intervention for substance use in pregnancy that improves maternal-infant outcomes and leads to lower overall costs by an amount significantly greater than the costs of the program.
Authors: Kelly C Young-Wolff; Lue-Yen Tucker; Mary Anne Armstrong; Amy Conway; Constance Weisner; Nancy Goler Journal: Matern Child Health J Date: 2020-04
Authors: Lynn Huynh; Mark McCoy; Amy Law; Kevin N Tran; Senta Knuth; Patrick Lefebvre; Sean Sullivan; Mei Sheng Duh Journal: Pharmacoeconomics Date: 2013-11 Impact factor: 4.981
Authors: Kelly C Young-Wolff; Varada Sarovar; Lue-Yen Tucker; Deborah Ansley; Nancy Goler; Amy Conway; Allison Ettenger; Tara R Foti; Qiana L Brown; Ellen T Kurtzman; Sara R Adams; Stacey E Alexeeff Journal: JAMA Netw Open Date: 2022-06-01
Authors: Davida M Schiff; Erin C Work; Serra Muftu; Shayla Partridge; Kathryn Dee L MacMillan; Jessica R Gray; Bettina B Hoeppner; John F Kelly; Shelly F Greenfield; Hendrée E Jones; Timothy E Wilens; Mishka Terplan; Judith Bernstein Journal: J Subst Abuse Treat Date: 2022-03-18
Authors: A Thomas McLellan; Joanna L Starrels; Betty Tai; Adam J Gordon; Richard Brown; Udi Ghitza; Marc Gourevitch; Jack Stein; Marla Oros; Terry Horton; Robert Lindblad; Jennifer McNeely Journal: Public Health Rev Date: 2014-01
Authors: Robert Rosenheck; Douglas Leslie; Kyaw Sint; Haiqun Lin; Delbert G Robinson; Nina R Schooler; Kim T Mueser; David L Penn; Jean Addington; Mary F Brunette; Christoph U Correll; Sue E Estroff; Patricia Marcy; James Robinson; Joanne Severe; Agnes Rupp; Michael Schoenbaum; John M Kane Journal: Schizophr Bull Date: 2016-01-31 Impact factor: 9.306
Authors: Davida M Schiff; Shayla Partridge; Nina H Gummadi; Jessica R Gray; Sara Stulac; Eileen Costello; Elisha M Wachman; Hendrée E Jones; Shelly F Greenfield; Elsie M Taveras; Judith A Bernstein Journal: Acad Pediatr Date: 2021-04-24 Impact factor: 3.107